Milestone Scientific Issues Update on New Business Activities in China

PISCATAWAY, N.J., March 26 /PRNewswire-FirstCall/ -- Milestone Scientific Inc. (OTC Bulletin Board:MLSS.ob - News), the recognized leader in advanced injection technologies, today issued a formal corporate update relating to the Company's new business opportunities in China. Specifically, Milestone is currently working in concert with its Chinese distribution partner, China National Medicines Corporation (d/b/a "Sinopharm") to advance the STA System™ through the required regulatory review and approval process at the State Food and Drug Administration (SFDA) for the People's Republic of China. Upon receiving SFDA clearance, which Sinopharm expects within the next 90 to 120 days, Milestone expects to commence shipments of the STA System to China, pursuant to the terms and conditions defined in the three-year blanket purchase order issued to the Company by Sinopharm late last year.